Aptose tuspetinib combo achieves 100% CR/CRh at higher doses in newly diagnosed AML trial

Aptose Biosciences Inc.

TUS+VEN+AZA achieved 100% CR/CRh (6/6) at 80mg and 120mg doses, exceeding 66% expected from VEN+AZA alone.
CR/CRh in 7/8 (88%) FLT3 wildtype AML; responses across TP53, RAS, FLT3-ITD mutations.
No dose-limiting toxicities, QTc prolongation, differentiation syndrome, or prolonged myelosuppression seen.
Dosing at 160mg TUS level now ongoing; trial enrolling 18-24 patients by end of 2025.

item 7.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.